Samsung Bioepis Proves Keytruda Biosimilar Equivalence in Phase 3 as Hana Bank Launches 1.3T Won SME Fund

The Quick Take

• Samsung Bioepis demonstrated Phase 1 and Phase 3 clinical equivalence for its Keytruda biosimilar SB27 in global trials, a milestone for Korean biotech
• Hana Bank launched a 1.3 trillion won SME lending programme targeting small business owners through new and expanded loan products
• Korea's national pension fund depletion timeline is now 13 years more sensitive to a 1% return change than government projections suggested three years ago

Several significant Korean financial and market developments emerged on June 29, led by Samsung Bioepis announcing that its Keytruda biosimilar candidate SB27 met primary endpoints in both Phase 1 and Phase 3 global clinical trials, demonstrating bioequivalence to the original pembrolizumab immunotherapy. Simultaneously, Hana Bank unveiled a 1.3 trillion won inclusive finance programme targeting small business owners and self-employed individuals through newly launched and expanded loan products. Wall Street overnight gains — with the S&P 500 rising approximately 0.93% and the Nasdaq climbing 1.3% — also provided a constructive backdrop for Korean equity markets, with technology shares benefiting from the US rebound.

Samsung Bioepis's SB27 Phase 3 equivalence achievement is a commercially significant milestone for the Korean pharmaceutical sector. Keytruda is among the world's best-selling drugs, with global sales exceeding $25 billion annually, and biosimilar entry could create a multi-billion-dollar market opportunity for Samsung Bioepis and parent Samsung BioLogics. The Korean pension fund sensitivity analysis — showing that a 1% return improvement now delays depletion by 13 years versus the government's prior estimate of five years — highlights how National Pension Service investment returns have become the single most critical variable in Korea's long-term social security financing. Hana Bank's 1.3T won SME programme is a credit expansion signal for Korea's small business economy, with financial inclusion lending reducing risk premiums for underserved borrowers.

Watch Samsung Bioepis's FDA submission timeline for SB27 — a US approval filing date would set the commercial launch calendar for Keytruda biosimilar competition. The macro variable for Korea's pension fund stability is NPS investment return trajectory: if equities deliver above long-run averages in 2026-2027, the depletion clock recedes meaningfully without structural reform. Track Hana Bank's 1.3T won programme uptake rate through Q3 disclosures — SME loan demand is a leading indicator of Korean small business sector health. Also monitor Korea Kolmar's Q2 results against the Shinhan Securities revised target of 130,000 won, as K-beauty skincare export demand trends are a key revenue driver for the conglomerate's current growth phase.

Synthesized from 7 sources.